Worldwide Market Reports

Cardiovascular Disease Drugs Market Technology, Market Size, Regional Outlook, Competitive Strategies and Forecasts, 2027

Cardiovascular diseases are popularly known as heart diseases. These diseases are associated with circulatory system and heart. To list a few common cardiovascular diseases—rheumatic heart disease, hypertensive heart disease, inflammatory heart disease, ischemic heart disease, and cerebrovascular heart disease. High blood pressure causes hypertensive heart disease. Key concerns related to hypertensive heart disease are hypertrophy, heart failure, angina, and coronary heart disease. Brain blood vessels get affected by the cerebrovascular disease. Cerebrovascular disease common types are a stroke, vascular dementia, transient ischemic attack, and subarachnoid hemorrhage.


Seattle, WA -- (SBWIRE) -- 11/26/2019 -- Cardiovascular Disease is a major cause of death in the U.S. and rest of the world. These diseases are primarily related with heart and blood vessels disorders, such asischemic heart disease, dyslipidemia, stroke, thrombosis, atherosclerosis, coronary artery diseases, peripheral artery disease and others. These disorders are mainly reported due to obesity, high cholesterol, smoking, excessi alcohol, and poor lifestyle. According to the World Health Organization (WHO), Cardiovascular Disease is responsible for approximately 15 million deaths each year across the globe. The same source also states that it is a major cause of death in adults and accounts for 50% of total deaths worldwide.

For More Info and for a Sample Copy:

In recent time, increasing prevalence of heart diseases and extensive pipeline Drugs are some of the major drivers of global Cardiovascular Disease Drugs market. Increasing aging population and rising number of life-style diseases are also contributing in the growth of global Cardiovascular Disease Drugs market. Rising number of diabetic patients holds immense potential to the growth of global Cardiovascular Disease Drugs market.

In terms of geographic, North America dominates the global Cardiovascular Disease Drugs market. This is due to increased awareness about various heart diseases in the region. The U.S. represents the largest market for Cardiovascular Disease Drugs followed by Canada in North America. In Europe, Germany, the U.K., Spain, Italy and France holds major share of Cardiovascular Disease Drugs market. However, Asia is expected to show high growth rates in the next five years in global Cardiovascular Disease Drugs market. This is due to many companies constructing their R&D facilities in the region. Less stringent wages and availability of skilled labor attracts manufacturing companies to invest in Asia. In addition, increasing awareness about heart related problems is also supporting in the growth of Cardiovascular Disease Drugs market in the region. Japan, China and India are expected to be the fastest growing Cardiovascular Disease Drugs markets in Asia.

Presently, antihypertensive Drug class holds the largest share of the global Cardiovascular Disease market in terms of revenue. The dominance of this Drug classis primarily witnessed due to presence of multibillion Drugs such as Diovan and Benicar brands. On the contrary, thrombolytic Drugs currently accounts for a small market share but is expected to grow at the fastest rate in future.

Geographically, North America accounted for the highest market share in 2013 due to high awareness about the heart diseases. According to the Centers for Disease Control and Prevention (CDC), every year about 610,000 people in America die of heart diseases. Likewise, annually 735,000 Americans are victims of heart attacks. Thus, increasing incidence of heart attacks in North America would surge the demand for Cardiovascular Disease Drugs. However, Asia-Pacific region is expected to showcase the fastest growth rate in the future due to rise in aging population, increasing awareness and other factors.

Some of the Major Companies operating in the global Cardiovascular Disease Drugs market are Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Takeda Pharmaceutical Co. Ltd., Novartis AG, Forest Laboratories Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Pfizer Inc. and Solvay SA.

Cardiovascular Disease Drug market is expected to demonstrate healthy growth rate due to the increasing incidence of population suffering from Cardiovascular Disease and rising number of obese and diabetes patients. Poor life style, geriatric population and presence of high number of innovative Drugs under the clinical studies are other key factors expected to fuel the market growth. Development of Drugs for a broad range of applications is a major challenge faced by the manufacturers operating in this industry. Thus, for addressing the unmet needs, researchers are focusing on development of cell-based therapies. For instance, Darapladib (GlaxoSmithKline Inc., UK), is a lipoprotein-associated phospholipase A2 inhibitor, Dabigatran (Pradaxa; Boehringer Ingelheim, USA) is direct thrombin inhibitor. In addition, apart from ingestion of Drugs through conventional mode (oral and parenteral),various advanced devices are also being introduced in the market that facilitate Drug delivery by mode of Drug eluting stents, balloons, and Drug eluting vascular grafts. Hence, based on abovementioned factors, Cardiovascular Disease Drugs market is anticipated to witness significant growth in the future.

Key features of this report:
- Drivers, restraints, and challenges shaping the Cardiovascular Disease Drugs market dynamics
- Latest innovations and key events in the industry
- Analysis of business strategies of the top players
- Cardiovascular Disease Drugs market estimates and forecasts(2018 -2027)

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter's five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Place an Enquiry For Complete List of Key Players: